PASG - Passage Bio Inc

PASG - Passage Bio Inc

https://www.passagebio.com

Recent News

Powered by Alpha Vantage

Passage Bio to Participate in H.C. Wainwright 27th Annual Global Investment Conference - Passage Bio ( NASDAQ:PASG )

Benzinga • 2 weeks, 4 days ago • score: 0.39

PHILADELPHIA, Aug. 28, 2025 ( GLOBE NEWSWIRE ) -- Passage Bio, Inc. PASG, a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that management will participate in the H.C.

Passage Bio to Participate in H.C. Wainwright 27th Annual Global Investment Conference

GlobeNewswire • 2 weeks, 4 days ago • score: 0.41

PHILADELPHIA, Aug. 28, 2025 ( GLOBE NEWSWIRE ) -- Passage Bio, Inc. ( NASDAQ: PASG ) , a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that management will participate in the H.C.

Passage Bio Announces 1-for-20 Reverse Stock Split - Passage Bio ( NASDAQ:PASG )

Benzinga • 2 months ago • score: 0.08

PHILADELPHIA, July 10, 2025 ( GLOBE NEWSWIRE ) -- Passage Bio, Inc. ( "Passage Bio" or the "Company" ) PASG, a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that its Board of Directors ( "Board" ) has approved ...

Passage Bio Announces 1-for-20 Reverse Stock Split

GlobeNewswire • 2 months ago • score: 0.08

PHILADELPHIA, July 10, 2025 ( GLOBE NEWSWIRE ) -- Passage Bio, Inc. ( "Passage Bio" or the "Company" ) ( NASDAQ: PASG ) , a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that its Board of Directors ( "Board" ) ...

Passage Bio ( PASG ) Upgraded to Buy: Here's What You Should Know

Zacks Commentary • 6 months, 1 week ago • score: 0.32

Passage Bio (PASG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Passage Bio ( PASG ) Upgraded to Buy: Here's What You Should Know

Zacks Commentary • 6 months, 1 week ago • score: 0.32

Passage Bio (PASG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Passage Bio to Participate in Upcoming Investor Conferences - Passage Bio ( NASDAQ:PASG )

Benzinga • 6 months, 2 weeks ago • score: 0.41

PHILADELPHIA, Feb. 26, 2025 ( GLOBE NEWSWIRE ) -- Passage Bio, Inc. PASG, a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced management will participate in the following upcoming investor conferences:

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Passage Bio, Inc., a genetic drug company, develops transformative therapies for rare monogenic central nervous system (CNS) diseases. The company is headquartered in Philadelphia, Pennsylvania.

52W High

$26.60

52W Low

$5.12

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.82

Valuation

Attractive

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

0.18

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

0.87

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

0.60

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

0.21%

Institutions (25–75% balanced)

54.50%

Shares Outstanding

3,178,700

Float

2,867,200

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

0

Gross Profit (TTM)

0

EPS (TTM)

39.40

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-0.88%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Value

N/A

Previous

N/A

Trend

—

Signal Cross

No cross

As of

—